Two research teams will carry out UK-wide trials to identify accurate and quick blood tests that can diagnose dementia, in a bid to improve the UK’s diagnosis rate.
Research teams at University College London, and Dementias Platform UK based at the University of Oxford, will capitalise on recent breakthroughs in potential dementia blood tests, and generate the evidence needed for them to be validated for use in the NHS within the next 5 years.
The teams make up the Blood Biomarker Challenge – a multi-million pound award given by Alzheimer’s Society, Alzheimer’s Research UK and the National Institute for Health and Care Research and Gates Ventures including £5m raised by players of People’s Postcode Lottery. The project aims to revolutionise dementia diagnosis.
Both teams will recruit participants from sites spread across the country, to ensure their findings are applicable to the whole of the UK’s diverse population.
Timely and accurate diagnosis of the diseases that cause dementia, such as Alzheimer’s disease, is crucial as it means people can access vital care and support and take part in medical research. This will be even more imperative if new treatments are approved for use in the NHS, as these work best for people in the earliest stage of their disease.
Currently, people are usually diagnosed using memory tests and brain scans. These are less accurate than ‘gold standard’ tests like PET scans or lumbar punctures, which can confirm what type of dementia they have. However, only 2% of people can access these specialist tests.
Blood tests for diagnosing dementia
In recent years, a number of different blood tests for diagnosing dementia have shown very promising results in research settings. But they have yet to be tested widely in clinical settings in the UK.
The READ-OUT* team will be led by Dr Vanessa Raymont, Professor James Rowe and Dr Ivan Koychev with Dementias Platform UK researchers from the Universities of Oxford and Cambridge. They will test multiple existing and novel blood tests, looking at a range of types of dementia, including Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies. The researchers will also look at whether the blood tests can help detect these diseases at various stages.
Led by Professor Jonathan Schott and Dr Ashvini Keshavan at University College London, the ADAPT team** will focus on the most promising biomarker for Alzheimer’s disease, called p-tau217. This reflects levels of two hallmark proteins found inside the brain in Alzheimer’s disease – amyloid and tau. The researchers will carry out a clinical trial to see whether measuring p-tau217 in the blood increases the rate of diagnosis for Alzheimer’s disease both in people with early dementia, but also in those with mild, progressive problems with memory.
These complementary research approaches will maximise the chances of providing the evidence needed to prove that blood tests are ready for use in the NHS. They will pave the way for them to be made available to all who might benefit within the next 5 years.
With more than half of all local authority districts in England failing to meet the government’s target dementia diagnosis rate of 66.7%, and with new drugs on the horizon which appear to slow early Alzheimer’s disease, experts from both charities and the research teams agree that change is needed.
Professor Jonathan Schott, Alzheimer’s Research UK Chief Medical Officer and Professor of Neurology, UCL Queen Square Institute of Neurology, said: “An early, accurate diagnosis of Alzheimer’s disease is already important, allowing people to access to appropriate care and medications. If, as we hope, new treatments that can slow down Alzheimer’s disease become available soon, then this will be vital. This would pave the way for fair and equitable access to new and potentially life-changing treatments to all who might benefit.”
Dr Vanessa Raymont, Associate Director, Dementias Platform UK and Senior Clinical Researcher, University of Oxford, said: “Since I first stepped into a memory clinic 30 years ago there has thankfully been a shift in the way society thinks about dementia. There was previously a feeling that this was just another part of aging, but now we’re seeing that people want to know more about their condition and they want a diagnosis as it helps them access the support they need. Both my parents lived with dementia so I know firsthand the devastation this disease causes, and how a timely and accurate diagnosis can benefit people and their families.”
Fiona Carragher, Director of Research and Influencing at Alzheimer’s Society, said: “Dementia is the UK’s biggest killer, yet a third of people living with dementia don’t have a diagnosis, which means they’re not able to access care and support. An early and accurate diagnosis is also going to be vital in the future for identifying people who are most likely to benefit from new treatments, which are now within reach.
At the moment only 2% of people with dementia can access the specialised tests needed to demonstrate eligibility for new treatments, leading to unnecessary delays, worry and uncertainty. Blood tests are part of the answer to this problem – they’re quick, easy to administer and cheaper than current, more complex tests. I’ve spent decades working in research and the NHS and, after years of slow progress, it feels like we’re on the cusp of a new chapter on how we treat dementia in this country.
Fiona Carragher, Director of Research and Influencing at Alzheimer’s Society
Dr Sheona Scales, Director of Research at Alzheimer’s Research UK, said: “We’ve seen the enormous potential that blood tests are showing for improving the diagnostic process for people and their loved ones in other disease areas. Now we need to see this same step-change in dementia, which is the greatest health challenge facing the UK. “It’s fantastic that through collaborating with the leading experts in the dementia community, we can look to bring cutting-edge blood tests for diagnosing dementia within the NHS. And this will be key to widening access to groundbreaking new treatments that are on the horizon.”
For more information about the Blood Biomarker Challenge and how to take part, please visit: www.dementiasplatform.uk
You might also like:
Imaging presymptomatic Alzheimer’s disease
New twice weekly Alzheimer’s disease patch
A Tattoo on my Brain: A Neurologist’s Personal Battle Against Alzheimer’s Disease
* The READ-OUT team (REAl World Dementia OUTcomes) for the first 3 years will run a fact finding study that will take blood tests in around 20 Dementias Platform UK sites across the UK, involving 3000 people from diverse populations. In the final 2 years, they will run a clinical trial with 880 people to explore how having a blood test for dementia affects diagnosis and quality of life, patients and carers, impact on care and how the results should be communicated to patients.
**The ADAPT team (Alzheimer’s disease Diagnosis And Plasma pTau217) will establish a ptau217 assay for use in the NHS before conducting a clinical trial with 1100 participants. Half will receive their test results after 3 months and half after 12 months, in order to understand whether the test makes a difference to the care their receive, the cost of their care and their quality of life.
